Cognixion

Executive Summary

Cognixion is a neurotechnology company pioneering non-invasive brain-computer interface (BCI) systems to restore communication and control for individuals with severe motor impairments such as ALS. Its platform integrates neural signals, eye-tracking, and head pose to enable high-accuracy, real-time interaction, targeting assistive communication, clinical neurology, and smart home applications. Founded in 2015 and headquartered in Santa Barbara, the company operates at the intersection of digital health and neuroscience, leveraging AI to decode intent without requiring surgery. The global BCI market is projected to grow significantly, driven by aging populations and rising incidence of neurodegenerative diseases. Cognixion's non-invasive approach positions it favorably against invasive alternatives like Neuralink, offering safer, more accessible solutions. However, as a private company with limited disclosed funding, its path to commercialization hinges on regulatory approvals, clinical validation, and strategic partnerships. With a strong technological foundation and clear unmet need, Cognixion is poised to capture a niche within the broader neurorehabilitation and accessibility markets. The conviction score of 55 reflects promising technology offset by early-stage commercial risk.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for Assistive Communication BCI60% success
• Q2 2026Strategic Partnership with Major ALS Association or Rehabilitation Center70% success
• Q4 2026Launch of Next-Generation Wireless BCI Headset with Enhanced Accuracy50% success